Orexo and Sobi agree to advance feasibility study with AmorphOX
· Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery platform, AmorphOX® · The feasibility study confirmed that the biomolecule retained its activity after formulation with AmorphOX · Orexo has patent applications for AmorphOX formulations relating to biomolecules. Uppsala, Sweden – February 12, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company agreed with Swedish Orphan Biovitrum AB (publ.) (Sobi) to advance the successful exploratory feasibility study initiated last year.